FTXH – First Trust Nasdaq Pharmaceuticals ETF
First Trust Nasdaq Pharmaceuticals ETF (FTXH) is a Health ETF, issued by First Trust, $1B in assets, 0.60% expense ratio.
Returns as of Oct 23, 2026: 1 week +2.4%, 1 year +44.0%.
Invests 90% in Nasdaq Pharmaceuticals Index, targeting liquid U.S. pharmaceutical companies. Non-diversified sector focus.
Top holdings
- MRK – Merck & Company Inc, 7.6%
- ABBV – AbbVie Inc, 7.1%
- JNJ – Johnson & Johnson, 6.9%
- LLY – Eli Lilly and Company, 6.9%
- BMY – Bristol-Myers Squibb Company, 6.6%
- BIIB – Biogen Inc, 3.6%
- VTRS – Viatris Inc, 3.6%
- VRTX – Vertex Pharmaceuticals Inc, 3.4%
- CAH – Cardinal Health Inc, 3.3%
- REGN – Regeneron Pharmaceuticals Inc, 3.3%
- PFE – Pfizer Inc, 3.2%
- AMGN – Amgen Inc, 3.2%
- GILD – Gilead Sciences Inc, 3.1%
- INCY – Incyte Corporation, 2.5%
- UTHR – United Therapeutics Corporation, 2.4%
- JAZZ – Jazz Pharmaceuticals PLC, 2.4%
- ILMN – Illumina Inc, 2.2%
- ZTS – Zoetis Inc, 1.8%
- EXEL – Exelixis Inc, 1.7%
- CRL – Charles River Laboratories, 1.7%
- HALO – Halozyme Therapeutics Inc, 1.6%
- MEDP – Medpace Holdings Inc, 1.5%
- TXG – 10X Genomics Inc, 1.3%
- BMRN – Biomarin Pharmaceutical Inc, 1.2%
- NBIX – Neurocrine Biosciences Inc, 1.2%